Bibliographic Details
| Title: |
Pre‐clinical and early clinical considerations for the development of non‐hormonal contraceptives for men. |
| Authors: |
Johnston, Daniel S.1 (AUTHOR) Daniel.Johnston@NIH.gov |
| Source: |
Andrology. Oct2024, Vol. 12 Issue 7, p1558-1567. 10p. |
| Subject Terms: |
*MALE contraceptives, *DRUG development, *CONTRACEPTION, *INVESTORS, *CONTRACEPTIVES |
| Abstract: |
Introduction: This manuscript presents non‐hormonal male contraceptive development in the context of mitigating risk to investigators and investors. Objective: The manuscript uses examples to illustrate drug development principles to move a project from discovery to development. The content is intended for those with reproductive biology backgrounds without significant exposure to drug development—particularly early‐stage targeted drug development—and those with general interest in developing non‐hormonal methods of contraception. Conclusion: The goal of issues addressed in this manuscript is to facilitate the advancement of innovative male contraceptives into late‐stage clinical trials, while keeping in mind early recognition of program deficiencies and development of mitigation strategies, or reassignment of limited, valuable resources. [ABSTRACT FROM AUTHOR] |
|
Copyright of Andrology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
